SAB Biotherapeutics shareholders elect Spragens and Link as Class II directors, ratify auditor

SAB Biotherapeutics, Inc.

Shareholders elected Jeffrey G. Spragens and David Link as Class II directors for three-year terms expiring at 2026 annual meeting.
Appointment of Mayer Hoffman McCann P.C. as independent auditor for FY 2023 ratified with 37.25M votes for, 33K against.
Over 37.5M shares voted, representing 74.45% of outstanding shares, constituting a quorum.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-06-29 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-29

Exact text from the filing

Proposal 2: Ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 Votes For Votes Against Abstentions 37,253,986 33,433 235,486

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

SAB Biotherapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-29 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-29

Exact text from the filing

Proposal 1: Election of two Class II directors Director Votes For Withheld Broker Non-Votes Jeffrey G. Spragens 30,399,580 403,139 6,720,186 David Link 30,402,160 400,559 6,720,186

View on SEC.gov

Browse all shareholder votes →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-019198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.